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Introduction: There are different strategies to analyze mortality in peritoneal dialysis (PD)
with different deﬁnitions for case, event, time at risk, and statistical tests. A common
method for the different registries would enable proper comparison to better understand
the  actual differences in mortality of our patients.
Methods: We  review and describe the analysis strategies of regional, national and interna-
tional registries. We  include actuarial survival, Kaplan–Meier (KM) and competitive risk (CR)eritoneal dialysis
ortality
urvival
analyses. We apply different approaches to the same database (GCDP), which show apparent
differences with each method.
Results: A total of 1890 incident patients in PD from 2003 to 2013 were included (55 years;
men 64.2%), with initial RRF of 7 ml/min; 25% had diabetes and a Charlson index of 3 [2–4];
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261 patients died, 380 changed to haemodialysis (HD) and 682 received a transplant. Annual
mortality rates varied up to 20% in relative numbers (6.4 vs. 5.2%) depending on the system
applied. The estimated probability of mortality measured by CR progressively differs from
the  KM over the years: 3.6 vs. 4.0% the ﬁrst year, then 9.0 vs. 11.9%, 15.6 vs. 28.3%, and 18.5
vs.  43.3% the following years.
Conclusions: Although each method may be correct in themselves and express different
approaches, the ﬁnal impression left on the reader is a number that under/overestimates
mortality. The CR model expresses better the reality of PD, where the number of patients
losing follow-up (transplant, transfer to HD) it is 4 times more than deceased patients and
only a quarter remain on PD at the end of follow up.
©  2015 Sociedad Espan˜ola de Nefrología. Published by Elsevier España, S.L.U. This is an
open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Cómo  debemos  analizar  y  describir  la  mortalidad  de  nuestros  pacientes:
experiencia  del  Grupo  Centro  Diálisis  Peritoneal
Palabras clave:
Diálisis peritoneal
Mortalidad
Supervivencia
r  e  s  u  m  e  n
Introducción: Existen distintas estrategias para analizar la mortalidad en diálisis peritoneal
(DP), con diferentes deﬁniciones de caso, evento, tiempo en riesgo y análisis estadístico.
Un  método común entre los distintos registros permitiría compararlos adecuadamente y
entender mejor las diferencias reales de mortalidad de nuestros pacientes.
Métodos: Revisamos y describimos las estrategias de análisis de los registros autonómicos,
nacional e internacionales. Incluimos análisis de supervivencia actuarial, Kaplan–Meier
(KM) y riesgos-competitivos (RC). Aplicamos los diferentes enfoques a la misma  base de
datos (GCDP), lo que permite mostrar las diferencias aparentes con cada método.
Resultados: Se incluyeron 1.890 pacientes incidentes en DP en el periodo 2003-2013 (55 an˜os;
64,2% varones), con FRR inicial de 7 ml/min; el 25% presentaba diabetes y un índice de Charl-
son  de 3 [2–4]. Fallecieron 261 pacientes, 380 pasaron a hemodiálisis (HD) y 682 recibieron
trasplante. Las tasas de mortalidad anual llegan a variar hasta un 20% en números relativos
(6,4  vs. 5,2%) según el sistema aplicado. La estimación de probabilidad de mortalidad por
RC  es inferior a KM en todos los an˜os: 3,6 vs. 4,0% el 1.er an˜o; 9,0 vs. 11,9%; 15,6 vs. 28,3% y
18,5  vs. 43,3% los siguientes.
Conclusiones: Aunque cada método pueda ser correcto en sí mismo y expresar diferentes
enfoques, la impresión ﬁnal que queda en el lector es un número que sobrestima la mor-
talidad. El modelo de RC expresa mejor la realidad en DP, donde el número de pacientes
que  pierden seguimiento (trasplante, paso a HD) cuadruplica al de los fallecidos y solo una
cuarta parte continúa en DP al ﬁnal del seguimiento.
©  2015 Sociedad Espan˜ola de Nefrología. Publicado por Elsevier España, S.L.U. Este es un
artículo Open Access bajo la licencia CC BY-NC-NDIntroduction
Mortality is theoretically the simplest and the most impor-
tant measure to evaluate the effect of our intervention in
a patient population with chronic renal disease.1 There are
many publications comparing survival between the different
stages of the disease,2 etiologies, renal replacement therapy
(RRT) techniques3–12 or between groups and countries.13,14
However, there is some controversy and disparity of results
in publications, and this is partly due to the lack of homo-
geneity in case deﬁnitions, statistical analysis approaches,
the management of censored patients censored and forms of
description and presentation of results.15,16 Therefore, differ-
ent records of patients with chronic kidney disease in RRT have
tried to deﬁne a model that summarizes the various ways of(http://creativecommons.org/licenses/by-nc-nd/4.0/).
measuring mortality.17, without having reached a consensus
model. It would facilitate the comparison between different
working groups on an important subject such as a patient
who receives RRT, and more  speciﬁcally, peritoneal dialysis
(PD). Our analysis is intended for that purpose, which applies
different methods on the same database (DB), allowing us to
compare and establish a methodological discussion on the
subject, for the purpose of advancing our knowledge and com-
prehend the information available in this ﬁeld.
Material  and  methodsThe Peritoneal Dialysis Center Group (GCDP) presents a
descriptive DB analysis that we have generated from a
prospective data collection since 2003, as described in
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reviously published.18 We  analyzed data from 1890 patient
ncidents in PD from 22 centers grouped in the territory of the
ommunities of Madrid, Castilla-Leon, Castilla-La Mancha,
xtremadura and Aragon.
The information is collected on an anonymous DB, with
esign, management and approved analysis by a scientiﬁc
ommittee that was independent of companies that support
he project analysis. Patients consent to inclusion on entering
n PD. Statistical analysis was carried out by SPSS v. 15.0 and
TATA v12 for CR analysis.
We conducted a ﬁrst descriptive analysis of the population
n line with what was previously published.18 The second part
f the study focuses on the mortality calculation in the last 7
ears (2007–2013) using the methodology referred in various
roups and regional, national and international registers (see
able 1) to compare and evaluate the reasons for the disparity.
Next, it expounds the main methods for estimating
ortality in a population, describing their advantages and
isadvantages.
ensity  of  mortality
t is calculated as the number of deaths in a year (usually a cal-
ndar year) divided by the total amount of time at risk. Each
atient provides his follow up time during the year. For exam-
le, a patient who  does not die during the year and begins on
 July provides 6 months and a patient that we  monitor for 6
onths until transferred and later the follow up is lost also
rovides this time. Data is expressed in deaths per patient-
ears. For example, 10 deaths in a group that accumulate 200
atient years at risk, can be expressed as 0.05 deaths/year-
atient or 5 deaths/100 patient-years, which is reduced to 5%
er year at risk. This method presents a mortality density
uring the time period. The validity of the estimate clearly
epends on the number of follow up patients lost and that
Table 1 – Registers and mortality calculation.
Registration Rate calculation 
REER (Spain) Deceased in calendar year/prevalent at th
year
RMRC (Catalonia) Deceased in calendar year/prevalent end 
(REER model)
REMER (Madrid) Deceased year/prevalent to year + death 
SICATA (Andalusia) Deaths year/(prevalent to year +½ death)
ERA-EDTA (Europe) Deceased in calendar year/prevalent end 
(REER model)
RDPLF (France) Not deﬁned in its publication 
USRDS (USA) Deceased in calendar year/prevalent at th
year. Only includes patients with >90 day
ANZDATA (Australia and
New Zealand)
Deceased in calendar year/prevalent end 
(REER model)
PD: peritoneal dialysis; HD: haemodialysis; KM: survival methods by Kapla(2):149–155 151
these are distributed randomly, with equal risk than those who
persist on the database.
Mortality
This index is calculated as the number of deaths during
the year (usually calendar) divided by patients at risk. Some
records assume that the prevalence of patients is stable for
one year and the average is very similar to an ordinary day
(for example, the previous year). Therefore, it is calculated
by dividing all the deceased during the year by the end of
year point prevalence. This approach is used by the Cata-
lan register,19 among others, and is more accurate for large
populations with few ﬂuctuations and low mortality, such as
general population studies. Other records use similar formulas
to estimate patients at risk, adding patients who  died, in the
denominator (REMER registry),20 or by calculating the average
prevalence of the period, i.e. the average number of patients
at the beginning and end of each year (Andalusian registry).21
Actuarial  survival
Actuarial survival calculates the survival probability per each
year from the initiation of PD. It collects follow up time for
each patient in ﬁxed intervals (usually annual) and estimates
the survival probability as the conditional probability for each
time interval. With this method, we can also calculate the
average incident rate per year (e.g. at 8 years’ follow-up). This
method is used by the French PD registry (RDPLF).22
Kaplan–Meier  survival  probabilityIt calculates the cumulative survival probability during a given
period of follow up. The model works with a dichotomous
variable: death or free event at the end of follow up event.
Survival curves
e end of KM since 2012 (with those autonomies that provide
individual data). According to 1st intention to treat
(TRS changes are not losses)
to year Actuarial  survival and graphics KM. According to 1st
TRS, TRS changes are losses
KM since 2008. According to 1st TRS, TRS changes
are losses
 Actuarial survival and KM. According to 1st TRS, the
deceased within two months after change of
dialysis technique, are assigned to 1st treatment,
rest are losses in 1st technical and restart the new
to year KM.  TRS only from day 91. According to 1st TRS, TRS
changes are losses
Actuarial survival and KM intention to treat (change
PD to HD remains in PD for analysis and monitoring
TX is follow up loss)
e end of
s in TRS
Actuarial survival and KM. TRS only from day 91.
According to 1st TRS, TRS changes are losses
to year KM.  According to 1st TRS, TRS changes are losses
n–Meier curves; TRS: renal replacement therapy; TX: transplant.
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Table 2 – Description of population according to type of output.
Continues in PD Death Transfer to HD Transplant Recovers FR Transfer Total
N (%) 493 (26.1) 261 (13.8) 380 (20.1) 682 (36.1) 40 (2.1) 34 (1.8) 1890
Average FRR and (SD) (ml/min) 7.2 (4.1) 6.2 (4.7) 6.3 (4.5) 7.2 (4) 11 (4.2) 5.9 (4) 7.0 (4.4)
Average age and (SD) in years 56.7 (15) 65.4 (13.5) 57.7 (16.6) 49.1 (13.3) 55.2 (18.2) 51.2 (16.7) 55.0 (15.6)
% CV 23.0 55.9 32.5 10 30.8 23.5 25.1
% DM 25.7 42.5 30.2 15 23.1 26.5 25.0
% Males 63.5 64.0 65.1 65.1 59.0 47.1 64.2
Average Charlson index and
(interquartile range)
3  (2–4) 2 (2–3) 3 (2–5) 4 (3–6) 3 (2–4) 2.5 (2–4) 3 (2–4)
itus; CV: cardiovascular events; SD: standard deviation; DM: diabetes mell
Monitoring is considered lost in patients whose follow up
is interrupted for another reason: transplantation, change to
haemodialysis (HD), transfers to another center or recovery of
renal function. These patients provide their follow-up to the
last event prior its patient follow up loss and subsequently
are removed from the analysis. This is the model used by
the EDTA23 register and by the French kidney disease register
(REIN),24 among others. In 2012, the REER began to introduce
this type of analysis by grouping several records from differ-
ent regions that share the information of individual data. In
the case of change of HD to PD or vice versa, the Andalusian
record assigns death to the ﬁrst technique if it occurs within
the ﬁrst 2 months after the change.21 The median of the time
period is the most used index and corresponds to the period
time in which survival probability is 50% or less. This method
has some limitations, such as the assumptions that the risk
is constant over time, something that is not always true. The
quality of the estimation depends on few losses during the
follow up with an uniform distribution through time and if
they are independent from the event of interest.
Some studies show the cumulative mortality curve, which
is the complementary of survival.
A  multiple  decrement  model  for  evaluating  competing
risks  (CR)
It estimates probability of survival by taking into account pos-
sible competitive events (CE). In this analysis, we consider as
CE renal function recovery, transplantation and transfer to
HD, because these situations modify survival probability. In
general, the prognosis is better in transplant patients than
in HD. The model works with 2 types of events, the main
event (deceased) and competitive (TX outputs, HD or recovery
of renal function). The remaining patients who do not com-
plete their follow up are considered lost. This model assumes
that the various outputs are independent of each other. The
Table 3 – Rates and percentages.
2007 2008 
Death (n) 36 35 
Prevalent end of year (n) 405 385 
 patients-year 406.4 406.4 
No. of deaths/100 patients-year 8.9 8.6 
% of deaths/prevalent 8.9 9.1 
% of deaths/(prevalent + deaths) 8.2 8.3 RRF: residual renal function.
analysis is presented as two cumulative event curves, one for
competitive events and another for mortality.
Results
It included 1890 patients with an overall follow up time of 3.633
years, with an average follow up of 1.92 years/patient (range
1 month to 10.5 years). At the end of follow up there were
261 deaths (13.8%), 380 transfers to HD (20.1%), 682 receive
a renal transplant (36.1%), 40 recover renal function (2.1%).
Thirty four patients were transferred to other centers external
to GCDP (1.8%). Finally, the remaining 493 patients continue in
PD (26.1%).
The descriptive analysis of the population is summa-
rized in Table 2; it compares the characteristics of different
groups of patients classiﬁed according to their situation at the
end of follow-up. Age, gender distribution and comorbidity
associated with Charlson index, diabetes mellitus and car-
diovascular events before initiation of PD and residual renal
function are shown in Table 2.
It is analyzed an incident population since 2003, so that
during the early years there is a very low mortality rate
when compared to prevalent, obtaining biased mortality data.
Therefore, it was decided to perform the analysis of mortality
from 2007 to 2013, inclusive, when the proportions have been
balanced.
In Table 3 it is shown number of deaths and prevalents at
the end of the year, accumulated time and mortality rates and
lethality, according to the different methods revised.
In the mortality analysis through KM method (Fig. 1A) the
median survival is 6.4 years (95% CI: 5.9–7.0).Fig. 1B shows the results obtained using the multiple decre-
ment method, that calculates the mortality by evaluating
competing risks (transfer to HD, transplantation, renal func-
tion recovery).
2009 2010 2011 2012 2013
37 28 33 20 30
399 421 385 313 245
396.2 422.8 416.5 383.3 264.1
9.3 6.6 7.9 5.2 11.4
9.3 6.7 8.6 6.4 12.2
8.5 6.2 7.9 6.0 10.9
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Time (years) Time (years)
0.6
0.4
0.2
0.0
0.8
0.6
0.4
0.2
0.0
0
N: 1877 689 390 103 20562101236 N: 1877 689 390 103 20562101236
1 2 3 4 5 6 7 0 1 2 3 4 5 6 7
Per annum 2 years 3 years 4 years 5 years 6 years 7 years
Cumulative incidence (KM) 4.0 11.9 20.3 28.3 35.2 43.3 50.5
Cumulative incidence (CR ) 3.6 9.0 12.9 15.6 17.1 18.5 19.4
Fig. 1 – (A) Cumulative incidence calculated by the Kaplan–Meier method. (B) Incidence. Cumulative mortality estimated
using the method of multiple decrements. It shows the number of patients at risk at the bottom of the ﬁgure. Cumulative
m
t
a
C
D
O
o
E
i
m
l
b
t
i
t
o
e
p
r
i
t
a
f
m
g
t
h
o
wortality through both methods is shown in the table.
When comparing both methods (KM vs. CR), we  observed
hat cumulative mortality is similar in the ﬁrst year. In the KM
nalysis, this percentage increases more  rapidly than in the
R model, thus overestimating mortality.
iscussion
ur paper aims to highlight the disparity between results
btained with different mortality analysis methods in PD.25
ach method is correct in itself and tries to reﬂect mortal-
ty, but does not express the same and transmits a different
essage to the reader and hinders comparison between pub-
ications. Performing these analyses on the same DB, that has
een proven to be reliable and proven to, helps to understand
he methodological details of these differences. For example,
n 2012 rates vary from 5.2 to 6.4% depending on the method;
his represents a difference greater than 20%.
In analyses performed by our group over 10 years, we
bserved differences in estimation of the mortality rates in
arly years, because the incident patients prevail over the
revalent.20,21 This difference disappears from 2006, and rates
emain stable when the initial effect of higher survival rate of
ncident patients is no longer present.20,21
There are some limitations in the way that REER calculates
he mortality rate.26 This record assumes that the population
t risk is constant throughout the follow up time and, there-
ore, is the same as the last day of the year on average. This
ay not be so in programs in growth or decrease, because it
enerates more  errors when the sample is smaller and greater
he proportion of deaths. It can also be signiﬁcantly affected by
igh transplantation rates (as in the Autonomous Community
f Madrid). Therefore, it does not seem to be an appropriate
ay to calculate mortality, especially in small samples such asa particular nephrology service, where there may be excessive
ﬂuctuations in consecutive years. Our recommendation is to
calculate the actual time at risk for each patient and reduce
the rate per patient-year.
The mortality analysis through KM is complete and
descriptive, but we  should bear in mind that it should meet
the conditions for the application of the method. The death
risk for our patients tends to be lower at the beginning, and
the model requires that this risk is uniform over time in PD.
Also, there is a crucial percentage of PD outputs with living
patients. For example, in our study and after 10 years follow
up, the proportion of patients considered lost (TX, transfer to
HD, renal function recovery) quadruples patient deaths (1162
vs. 261). Most records report PD distribution outputs in three
thirds, nearly the same as death, transplants and change to
HD.25 However, in our group, the TX represent more  than 50%
of total PD program outputs. At the end of our follow up more
than half of our patients are follow up losses, without reach-
ing death event. Therefore, Kaplan–Meier analysis may not
express an accurate impression.
CR model proposed here, analyses these situations differ-
ently and better reﬂects what is happening with our patients.
In this model, these patients lost differ according to their out-
put (TX, HD, renal function recovery) establishing each as an
independent event that competes with the rest. Thus, it is
expected that transplant patients had a less life-threatening
risk than those who transfer to HD, which can thus explain the
differences in the TX/HD relationship between analysis using
KM or CR.
Despite being the best suited model from our point of view,
there are also some limitations in the analysis carried out.
The ﬁrst is the lack of follow-up when the patient abandons
the technique, unable to determine the evolution of each
one of them. For example, there are situations where certain
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terminally ill patients are transferred to HD and die a few
weeks or months later. Another limitation is the actual time
in the technique that the patients provide in the analyzed
data. The average duration of the procedure per patient is
too short (approximately 2 years) and remains stable after 10
years of DB operation. As already published in other articles
of our group, this short follow up time is a consequence of
the high rate of departures to TX in a population that, by
demographic characteristics and privileged clinical situation,
has faster access to a kidney transplant as deﬁnitive TRS.27
Finally, we must consider other factors that inﬂuence other
PD mortalities in each registry.28 Aspects such as the assign-
ment/election policy of the ﬁrst RRT can affect the different
proﬁle of patients in each technique. Mandatory allocation
models (e.g. Hong Kong model) or priority allocation (model
PD-ﬁrst) behave differently than our Free election.29 In the
Spanish model, it observes a PD inclusion rate around 15%
and a positive selection of younger patients and less morbidity
for this technique. We must also consider the general charac-
teristics of the population, with different ages or prevalence
of obesity and diabetes mellitus, which is very relevant when
compared with records from the US. Finally, as the US records
exclude patients who  do not survive the ﬁrst 90 days of treat-
ment, making it impossible to compare with our results. The
applicability of our environment analysis of other groups or
records depends on these factors, which determine the exter-
nal validity of the published work.
The GCDP DB is ﬁlled in prospectively by the clinics directly
responsible for patient clinical follow up, which ensures
greater accuracy than those administrative forms used in
other records.
Conclusion
The actual mortality in a population might seem over – or
underestimated depending on the chosen method to analyze
and present. This analysis, using different methods on the
same DB, helps to understand these differences. Finally, it
seems reasonable, given the disparity of formulas, establish
a shared method for all registries to standardize a unique sys-
tem for comparing information from different international
registries. CR model is appropriate in situations of high rate of
losses in the follow up.
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